Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14208869 | 0.98 | LMNA (0.41) | LMNAPOLBTSHRALOX12ACHE | |
| SCHEMBL19849752 | 0.92 | LMNA (0.38) | LMNAPOLBTSHRALOX12ACHE | |
| SCHEMBL987145 | 0.84 | CALM1 (0.43) | TSHRALOX12SMN1; SMN2IDO1TDP1 | |
| SCHEMBL988388 | 0.81 | NR1H2 (0.49) | LMNAPOLBTSHRALOX12ACHE | |
| SCHEMBL22374958 | 0.80 | NR1H2 (0.34) | TSHRTAAR1 | |
| SCHEMBL29168473 | 0.78 | ALDH1A1 (0.42) | LMNATSHRCYP2C19HTTIDO1 | |
| SCHEMBL25491508 | 0.78 | ESRRG (0.41) | LMNAACHESMN1; SMN2NPC1RAB9A | |
| SCHEMBL14208897 | 0.78 | TDP1 (0.42) | LMNAPOLBTSHRALOX12ACHE | |
| SCHEMBL14208868 | 0.77 | LMNA (0.46) | LMNAPOLBTSHRALOX12ACHE | |
| SCHEMBL10249525 | 0.76 | LMNA (0.38) | LMNAPOLBTSHRALOX12ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275427-B1 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-20130099171-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2013-04-25 | — | — | US | disclosed |
| US-8404879-B2 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2258707-B1 | Ruthenium silyl-arene complexes, and method for production thereof | TAKASAGO PERFUMERY CO LTD (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7880025-B2 | complexing trimethyl(4-methyl-1,4-cyclohexadienyl)silane with ruthenium chloride to produce RuCl2 [trimethyl (4-methyl-1,4-cyclohexadienyl) silane] | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2275427-A1 | Ruthenium-diamine complex and methods for producing optically active compounds | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258707-A1 | Ruthenium silyl-arene complexes, and method for production thereof | Takasago International Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | SPR, LSS, SRI | LMNA 4231/4885POLB 4534/4885TSHR 4573/4885 |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH5, AOC1, ADH1A | LMNA 3481/4885POLB 1131/4885TSHR 2921/4885 |
| US-20130099171-A1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | L1CAM, EFNA1, EPCAM | LMNA 2573/4885POLB 1651/4885TSHR 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.